Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,489 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (403)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05489289 | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | recruiting | Phase 3 | 570 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
| recruiting |
| Phase 3 |
| 469 |
| AkesoINDUSTRY |
| 1 |
| Mar 12, 2025 |
| clinicaltrials |
| NCT06864221 | Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma | recruiting | — | 260 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06871930 | Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease | not yet recruiting | — | 150 | Assiut UniversityOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06873269 | Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma(TARE for HCC) | recruiting | — | 100 | Universitair Ziekenhuis BrusselOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03895359 | Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma(TACE) | recruiting | Phase 3 | 128 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04745390 | Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer(SAVIOR) | recruiting | N/A | 110 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06870942 | Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05195294 | Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | not yet recruiting | Phase 2 | 55 | Lion TCR Pte. Ltd.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06742892 | A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy | recruiting | Phase 2 | 90 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06867432 | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06864195 | A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions(VOCAL2) | recruiting | — | 750 | Imperial College LondonOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06862934 | Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments(iCOLA) | recruiting | — | 14 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06208462 | Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | recruiting | Phase 1 | 80 | Sichuan UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06852287 | Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer(GOLD-HAIC) | recruiting | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04299581 | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04954781 | TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05010681 | Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05057845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06849180 | Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data | recruiting | — | 198 | Zhongda HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06841185 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 656 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT05992220 | Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion(ALERT-HCC) | recruiting | Phase 2 | 138 | Asan Medical CenterOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04344158 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 3 | 648 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06397235 | DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC | recruiting | Phase 2 | 130 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06836518 | Sialic Acid in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Sohag UniversityOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06836778 | Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices | not yet recruiting | N/A | 100 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT06594744 | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC(P-HCC-CVL) | recruiting | Phase 4 | 120 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06821958 | Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF) | recruiting | N/A | 36 | Charite University, Berlin, GermanyOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06822985 | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma(QL1706) | not yet recruiting | Phase 1 | 21 | Wan-Guang ZhangOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06823050 | A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC | not yet recruiting | — | 59 | Xuhua DuanOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05520788 | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing(CCGLC-006) | recruiting | — | 200 | Tongji HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05557578 | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence(GOT) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05920863 | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors | recruiting | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05984511 | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | recruiting | N/A | 234 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05596630 | Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC | recruiting | N/A | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06542796 | Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma | recruiting | N/A | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06813508 | Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH(BOMASH) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06333561 | HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06806579 | Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma(ARTE) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06492395 | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | recruiting | Phase 3 | 178 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06798194 | Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma | not yet recruiting | — | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03695952 | A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06707233 | Y-90 SIRT for Unresectable HCC Larger Than 7cm | recruiting | Phase 2 | 33 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06792097 | Ga-68 Dolacga PET Scan in HCC Under RFA(HCC; RFA) | not yet recruiting | — | 10 | National Taiwan University HospitalOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06788353 | Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma | recruiting | — | 500 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2025source: clinicaltrials